Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells

被引：0
|
作者：
Yu, Hao [1 ]
Shi, Ni [1 ]
Pan, Zui [1 ]
Chen, Tong [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1253
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Radiosensitization by the Dual PI3K/mTOR inhibitor NVP-BEZ235
    Cerniglia, George J.
    Karar, Jayashree
    Koumenis, Constantinos
    Maity, Amit
    CANCER RESEARCH, 2012, 72
  • [2] Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235
    Maity, A.
    Cerniglia, G. J.
    Karar, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S84 - S85
  • [3] Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    Roulin, Didier
    Waselle, Laurent
    Dormond-Meuwly, Anne
    Dufour, Marc
    Demartines, Nicolas
    Dormond, Olivier
    MOLECULAR CANCER, 2011, 10
  • [4] Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
    Didier Roulin
    Laurent Waselle
    Anne Dormond-Meuwly
    Marc Dufour
    Nicolas Demartines
    Olivier Dormond
    Molecular Cancer, 10
  • [5] SYNTHESIS AND PROCESS OPTIMIZATION OF PI3K/MTOR DUAL INHIBITOR NVP-BEZ235
    Xu, T. S.
    Lei, F.
    Tao, H.
    Li, J. Q.
    Zhang, Z. W.
    Wang, L. X.
    Xu, S.
    Zheng, P. W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 31 - 31
  • [6] Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
    Xie, Chencheng
    Freeman, Matthew J.
    Lu, Huarui
    Wang, Xiaohong
    Forster, Colleen L.
    Sarver, Aaron L.
    Hallstrom, Timothy C.
    ONCOTARGET, 2017, 8 (24) : 38084 - 38098
  • [7] Combination strategy of gemcitabine with the dual PI3K/mTOR inhibitor NVP-BEZ235 in pancreatic cancer cells.
    Hausmann, E.
    Glienke, W.
    Bergmann, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] NVP-BEZ235, a dual PI3K/mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Nonaka, Michiko
    Sato, Seiya
    Naniwa, Jun
    Uegaki, Kazunori
    Sato, Shinya
    Shimada, Muneaki
    Terakawa, Naoki
    Kigawa, Junzo
    Harada, Tasuku
    CANCER RESEARCH, 2011, 71
  • [9] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    Bhende, P. M.
    Park, S. I.
    Lim, M. S.
    Dittmer, D. P.
    Damania, B.
    LEUKEMIA, 2010, 24 (10) : 1781 - 1784
  • [10] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    P M Bhende
    S I Park
    M S Lim
    D P Dittmer
    B Damania
    Leukemia, 2010, 24 : 1781 - 1784
12345